Cantor Fitzgerald Issues Positive Forecast for Hyperion DeFi (NASDAQ:HYPD) Stock Price

Hyperion DeFi (NASDAQ:HYPD) had its target price upped by research analysts at Cantor Fitzgerald from $6.60 to $7.10 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 163.94% from the company’s current price.

Other analysts also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating and set a $7.30 price objective on shares of Hyperion DeFi in a research note on Tuesday. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. Finally, Zacks Research raised Hyperion DeFi from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.20.

Hyperion DeFi Stock Performance

Shares of HYPD stock opened at $2.69 on Thursday. The stock has a market cap of $40.78 million, a PE ratio of -0.27 and a beta of 2.53. The stock has a 50-day moving average of $2.92 and a 200-day moving average of $3.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.97 and a quick ratio of 1.97. Hyperion DeFi has a one year low of $2.34 and a one year high of $15.00.

Hyperion DeFi (NASDAQ:HYPD) last released its quarterly earnings data on Thursday, August 13th. The company reported $0.92 earnings per share for the quarter. The firm had revenue of $0.36 million for the quarter. As a group, sell-side analysts expect that Hyperion DeFi will post 1.71 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Hyunsu Jung bought 7,000 shares of Hyperion DeFi stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $3.70 per share, with a total value of $25,900.00. Following the purchase, the insider owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This trade represents a 0.51% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.50% of the company’s stock.

Institutional Trading of Hyperion DeFi

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Hyperion DeFi during the fourth quarter worth about $493,000. Renaissance Technologies LLC bought a new stake in shares of Hyperion DeFi in the fourth quarter worth $663,000. Focus Partners Advisor Solutions LLC acquired a new position in Hyperion DeFi during the fourth quarter worth $221,000. Geode Capital Management LLC bought a new position in Hyperion DeFi in the fourth quarter valued at $214,000. Finally, Redwood Wealth Management Group LLC increased its stake in Hyperion DeFi by 2.1% in the 1st quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after buying an additional 3,690 shares during the last quarter. 25.84% of the stock is currently owned by institutional investors.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.